Investor Relations

Upcoming Events

12th Annual Craig-Hallum Alpha Select Conference

Piper Sandler 33rd Annual Healthcare Conference

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447

Investor Relations

LifeSci Advisors, LLC
Timothy McCarthy, CFA
Managing Director, Relationship Manager
T: 212.915.2564

DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456
skellen@diamedica.com